Clinical Trials Logo

Adenocarcinoma Esophagus clinical trials

View clinical trials related to Adenocarcinoma Esophagus.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06044311 Not yet recruiting - Clinical trials for Adenocarcinoma Esophagus

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This interventional clinical trial aims to find ways of improving treatments for individuals with esophageal cancer. Laboratory-based studies show that using medicines that affect a protein called TGF-beta (TGFβ) can kill esophageal cancer cells in individuals who have localized esophageal adenocarcinoma and are being considered for standard-of-care chemoradiation prior to surgery. Participants of this study will take a pill called vactosertib for two weeks before starting standard of care chemoradiation. At the end of the two weeks of taking vactosertib, participants will have a Positron Emission Tomography Computer Assisted Tomography (PET CT) scan and undergo an endoscopy with a biopsy to determine if the vactosertib is working. After chemoradiation, participants will take vactosertib again for four weeks and then be considered for surgery.